<DOC>
	<DOC>NCT02972268</DOC>
	<brief_summary>Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy with Tamsulosin Monotherapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia</brief_summary>
	<brief_title>Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Over 45 years Benign Prostate Hyperplasia diagnosed by 20 mL &lt; TRUS Lower urinary tract symptom suggestive of benign prostate hyperplasia, who spontaneously agree to join and sign to the consent form Subjects who have a history of the lower urinary tract cancer, including prostate cancer and bladder cancer within the past 3 years Subjects who have acute urinary retention within 12 weeks before screening Subjects who have clinically significant severe cardiovascular disease(unstable angina, myocardial infarction or arrhythmia) within 24 weeks before screening Subjects who have hypersensitivity to investigational product Subjects who were suspected or confirmed neurogenic bladder, bladder neck structure, bladder diverticulum Subjects who have myasthenia gravis, narrow angle glaucoma Subjects who have hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption SBP &gt; 180 mmHg or DBP &gt; 100 mmHg HbA1c &gt; 9.0 % Subjects who are judged by the investigators to be unsuitable to participate in the clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>